Single Nucleotide Polymorphisms-SNPs
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Comparing Copy Number Variations and SNPs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Principles of Pharmacogenetics: Types of Genetic Variants
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Tao Jiang1, Lizhuo Li, Ying Wang
1From the Department of Neurology (TJ, JY), Laizhou People's Hospital, Laizhou, Shandong; Department of Critical Care and Emergency Medicine (LL), The Affiliated Hospital of Hainan Medical University, Haikou, Hainan; Emergency Department (LL), Shengjing Hospital of China Medical University, Shenyang, Liaoning; Department of Neurosurgery (YW, DM), Huashan Hospital, Fudan University, Shanghai, China; Brain Tumor Center (CZ), Cancer and Blood Diseases Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA; Department of Neurosurgery (YG, DZ, YB, YW), The First Hospital of China Medical University, Shenyang, Liaoning; Rush Alzheimer's Disease Center (JY); and Department of Neurological Sciences (JY), Rush University Medical Center, Chicago, IL, USA.
The genetic variant rs703842 in CYP27B1 is associated with reduced risk of multiple sclerosis (MS). This finding suggests a potential protective role for the C allele in MS susceptibility among Caucasians.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: